ASP Isotopes Announces Major Developments: Largest Silicon-28 Contract and Florida Radiopharmacy Acquisition

This heading captures the essence of the news, highlighting both the significant contract and the strategic acquisition, which are key points of interest for readers.

ASP Isotopes Expands Horizons with Major Silicon-28 Contract and Florida Acquisition

Washington, D.C. — October 13, 2025 — ASP Isotopes Inc. (NASDAQ: ASPI), a pioneering advanced materials company, has announced significant developments that promise to reshape its operational landscape. The company has secured its largest supply contract for enriched silicon-28 to date, with deliveries slated for the first quarter of 2026. In a strategic move to bolster its presence in the U.S. market, ASP Isotopes has also acquired an independent radiopharmacy in Florida, marking a pivotal expansion for its subsidiary, PET Labs Pharmaceuticals.

A Landmark Contract

The newly inked contract for enriched silicon-28 underscores ASP Isotopes’ growing influence in the isotopic materials sector, particularly in applications related to quantum computing and advanced semiconductor technologies. This isotopically pure silicon-28 is crucial for developing solid-state quantum computing, as it minimizes nuclear spin noise, thereby enhancing the performance of qubits.

Viktor Petkov, Chief Commercial Officer of ASP Isotopes, expressed enthusiasm about the contract, stating, “This significant customer order for silicon-28 underscores how our Electronic Gases strategy is gaining real traction across multiple end markets.”

Florida Acquisition: A Strategic Expansion

In addition to the silicon-28 contract, ASP Isotopes has acquired a Florida-based radiopharmacy, which currently offers SPECT services. The company plans to introduce PET services by 2027, leveraging PET Labs’ expertise to enhance its operational capabilities in the U.S. This acquisition is expected to be accretive to the company’s revenues, EBITDA, and earnings per share (EPS) in 2026.

Dr. Gerdus Kemp, CEO of PET Labs, emphasized the importance of this acquisition, stating, “This marks the first important step in the planned expansion of PET Labs outside South Africa. We aim to grow PET Labs into a global leader in the production of radioisotopes for oncology treatment.”

Future Prospects and Investor Engagement

ASP Isotopes is not resting on its laurels; the company is actively pursuing further expansion opportunities in the U.S. market. It has signed a non-binding term sheet for another potential acquisition and is in discussions with multiple independent radiopharmacies.

An investor access event is scheduled for November 12-13, 2025, where ASP Isotopes will provide insights into its growth strategy and the anticipated rollout of its PET services.

Conclusion

With these strategic moves, ASP Isotopes is positioning itself as a key player in the isotopic materials market, ready to meet the growing demand for high-purity silicon-28 and expand its footprint in the U.S. radiopharmaceutical sector. As the company gears up for a promising future, stakeholders and investors alike will be watching closely to see how these developments unfold.